Publications by authors named "Yutaka Fujiwara"

100Publications

Correlation between the expression of folate receptor alpha (FRα) and clinicopathological features in patients with lung adenocarcinoma.

Lung Cancer 2020 Jul 11;145:152-157. Epub 2020 May 11.

Department of Diagnostic Pathology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2020.05.002DOI Listing
July 2020

Clonal Hematopoiesis From Next Generation Sequencing of Plasma From a Patient With Lung Adenocarcinoma: A Case Report.

Front Oncol 2020 13;10:113. Epub 2020 Feb 13.

Division of Translational Genomics, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, Tokyo, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fonc.2020.00113DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7031249PMC
February 2020

Improved survival among patients enrolled in oncology phase 1 trials in recent decades.

Cancer Chemother Pharmacol 2020 02 19;85(2):449-459. Epub 2019 Nov 19.

Department of Experimental Therapeutics, National Cancer Center Hospital, 5-1-1, Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-019-03992-2DOI Listing
February 2020

Phase I study of ipatasertib as a single agent and in combination with abiraterone plus prednisolone in Japanese patients with advanced solid tumors.

Cancer Chemother Pharmacol 2019 08 21;84(2):393-404. Epub 2019 Jun 21.

Department of Medical Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-019-03882-7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6647215PMC
August 2019

Phase I study of BGT226, a pan-PI3K and mTOR inhibitor, in Japanese patients with advanced solid cancers.

Cancer Chemother Pharmacol 2019 08 12;84(2):337-343. Epub 2019 Jun 12.

Novartis Pharma K.K, Tokyo, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-019-03883-6DOI Listing
August 2019

Next-Generation Sequencer Analysis of Pulmonary Pleomorphic Carcinoma With a CD74-ROS1 Fusion Successfully Treated With Crizotinib.

J Thorac Oncol 2019 05;14(5):e106-e108

Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan; Cancer Medicine, Jikei University Graduate School of Medicine, Tokyo, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2019.01.005DOI Listing
May 2019

Lenvatinib in combination with everolimus in patients with advanced or metastatic renal cell carcinoma: A phase 1 study.

Int J Urol 2018 11 20;25(11):922-928. Epub 2018 Aug 20.

Department of Medical Oncology, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Koto-ku, Tokyo, Japan.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/iju.13776
Publisher Site
http://dx.doi.org/10.1111/iju.13776DOI Listing
November 2018

Global trends in the distribution of cancer types among patients in oncology phase I trials, 1991-2015.

Invest New Drugs 2019 02 7;37(1):166-174. Epub 2018 Aug 7.

Department of Experimental Therapeutics, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10637-018-0654-1DOI Listing
February 2019

Safety and pharmacokinetics of DS-6051b in Japanese patients with non-small cell lung cancer harboring fusions: a phase I study.

Oncotarget 2018 May 4;9(34):23729-23737. Epub 2018 May 4.

Department of Thoracic Oncology, National Hospital Organization Kyushu Cancer Center, Minami-ku, Fukuoka-shi, Fukuoka 811-1395, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.25263DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5955103PMC
May 2018

The first case of SMARCB1 (INI1) - deficient squamous cell carcinoma of the pleura: a case report.

BMC Cancer 2018 04 7;18(1):398. Epub 2018 Apr 7.

Department of Thoracic Oncology, National Cancer Center Hospital, 5-1-1, Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12885-018-4321-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5889546PMC
April 2018

Appearance of a BRAF Mutation Conferring Resistance to Crizotinib in Non-Small Cell Lung Cancer Harboring Oncogenic ROS1 Fusion.

J Thorac Oncol 2018 04;13(4):e66-e69

Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan; Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2017.11.125DOI Listing
April 2018

The genomic and epigenomic landscape in thymic carcinoma.

Carcinogenesis 2017 10;38(11):1084-1091

Division of Genome Biology, National Cancer Center Research Institute, Tokyo 104-0045, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/carcin/bgx094DOI Listing
October 2017

PD-L1 expression in neuroendocrine tumors of the lung.

Lung Cancer 2017 06 24;108:115-120. Epub 2017 Mar 24.

Department of Thoracic Oncology, National Cancer Center Hospital, Tsukiji 5-1-1, Chuo-ku, Tokyo 104-0045, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2017.03.006DOI Listing
June 2017

Efficacy and safety of osimertinib in a Japanese compassionate use program.

Jpn J Clin Oncol 2017 Jul;47(7):625-629

Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jjco/hyx050DOI Listing
July 2017

Do all patients in the phase I oncology trials need to be hospitalized? Domestic but outstanding issues for globalization of drug development in Japan.

Int J Clin Oncol 2017 Aug 14;22(4):780-785. Epub 2017 Mar 14.

Department of Experimental Therapeutics, National Cancer Center Hospital, 5-1-1, Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10147-017-1108-zDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5533862PMC
August 2017

Surveillance of protocol deviations in Japanese oncology registration trials: a single institute experience.

Invest New Drugs 2017 06 1;35(3):392-396. Epub 2017 Feb 1.

Clinical Trial Coordination and Support Office, National Cancer Center Hospital, Tokyo, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10637-017-0434-3DOI Listing
June 2017

Phase 1 study of abemaciclib, an inhibitor of CDK 4 and 6, as a single agent for Japanese patients with advanced cancer.

Cancer Chemother Pharmacol 2016 Aug 16;78(2):281-8. Epub 2016 Jun 16.

Department of Experimental Therapeutics, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-016-3085-8DOI Listing
August 2016

Randomized trial of standard pain control with or without gabapentin for pain related to radiation-induced mucositis in head and neck cancer.

Auris Nasus Larynx 2016 Dec 15;43(6):677-84. Epub 2016 Mar 15.

Department of Medical Oncology/Hematology, Kobe University Hospital, 7-5-2 Kusunoki-cho, Chuo-ku, Kobe, Hyogo 650-0017, Japan; Cancer Center, Kobe University Hospital, 7-5-2 Kusunoki-cho, Chuo-ku, Kobe, Hyogo 650-0017, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.anl.2016.02.012DOI Listing
December 2016

Validity of new methods to evaluate renal function in cancer patients treated with cisplatin.

Cancer Chemother Pharmacol 2016 Feb 20;77(2):281-8. Epub 2016 Jan 20.

Division of Medical Oncology/Hematology, Department of Medicine, Kobe University Hospital and Graduate School of Medicine, 7-5-2 Kusunoki-cho, Chuo-ku, Kobe, 650-0017, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-016-2966-1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4747994PMC
February 2016

Candidates for Intensive Local Treatment in cIIIA-N2 Non-Small Cell Lung Cancer: Deciphering the Heterogeneity.

Int J Radiat Oncol Biol Phys 2016 Jan 26;94(1):155-162. Epub 2015 Sep 26.

Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan; Advanced Clinical Research of Cancer, Juntendo University Graduate School of Medicine, Tokyo, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ijrobp.2015.09.026DOI Listing
January 2016

Phase I trial of volasertib, a Polo-like kinase inhibitor, in Japanese patients with advanced solid tumors.

Invest New Drugs 2016 Feb 2;34(1):66-74. Epub 2015 Dec 2.

Department of Thoracic Oncology, National Cancer Centre Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10637-015-0300-0DOI Listing
February 2016

Phase 1 study of galunisertib, a TGF-beta receptor I kinase inhibitor, in Japanese patients with advanced solid tumors.

Cancer Chemother Pharmacol 2015 Dec 3;76(6):1143-52. Epub 2015 Nov 3.

Department of Thoracic Oncology, National Cancer Center Hospital, Tsukiji 5-1-1, Chuo-ku, Tokyo, 104-0045, Japan.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s00280-015-2895-4
Publisher Site
http://dx.doi.org/10.1007/s00280-015-2895-4DOI Listing
December 2015

Degludec is superior to glargine in terms of daily glycemic variability in people with type 1 diabetes mellitus.

Endocr J 2016 31;63(1):53-60. Epub 2015 Oct 31.

Division of Rheumatology, Endocrinology and Nephrology, Hokkaido University Graduate School of Medicine, Sapporo 060-8638, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1507/endocrj.EJ15-0438DOI Listing
November 2016

Tremelimumab-associated tumor regression following after initial progression: two case reports.

Immunotherapy 2016 2;8(1):9-15. Epub 2015 Oct 2.

Department of Experimental Therapeutics, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.

View Article

Download full-text PDF

Source
https://www.futuremedicine.com/doi/10.2217/imt.15.89
Publisher Site
http://dx.doi.org/10.2217/imt.15.89DOI Listing
June 2016

Phase II study of amrubicin at a dose of 45 mg/m2 in patients with previously treated small-cell lung cancer.

Jpn J Clin Oncol 2015 Oct 31;45(10):941-6. Epub 2015 Jul 31.

Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jjco/hyv107DOI Listing
October 2015

Rapid improvement of glucagonoma-related necrolytic migratory erythema with octreotide.

Clin J Gastroenterol 2014 Jun 9;7(3):255-9. Epub 2014 Apr 9.

Department of Clinical Oncology, Osaka City General Hospital, Osaka, Japan,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12328-014-0471-9DOI Listing
June 2014

Current Status of Single-Agent Phase I Trials in Japan: Toward Globalization.

J Clin Oncol 2015 Jun 27;33(18):2051-61. Epub 2015 Apr 27.

All authors: National Cancer Center Hospital, Tokyo, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.58.4953DOI Listing
June 2015

A phase I study of resminostat in Japanese patients with advanced solid tumors.

Cancer Chemother Pharmacol 2015 Jun 7;75(6):1155-61. Epub 2015 Apr 7.

Department of Thoracic Oncology, National Cancer Center Hospital, 5-1-1, Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-015-2741-8DOI Listing
June 2015

A multi-institution phase II study of gemcitabine/cisplatin/S-1 (GCS) combination chemotherapy for patients with advanced biliary tract cancer (KHBO 1002).

Cancer Chemother Pharmacol 2015 Feb 5;75(2):293-300. Epub 2014 Dec 5.

Department of Clinical Oncology and Pharmacogenomics, Graduate School of Medicine, Kyoto University, 54 Shogoin-Kawahara-cho, Sakyo-ku, Kyoto, 606-8507, Japan,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-014-2648-9DOI Listing
February 2015

Effects of aprepitant on the pharmacokinetics of controlled-release oral oxycodone in cancer patients.

PLoS One 2014 14;9(8):e104215. Epub 2014 Aug 14.

Division of Medical Oncology/Hematology, Kobe University Graduate School of Medicine, Kobe, Japan; Cancer Center, Kobe University Graduate School of Medicine, Kobe, Japan.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0104215PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4133207PMC
April 2015